Complications with Fiberoptic Endoscopic Evaluation of Swallowing in 2,820 Examinations
Complications with Fiberoptic Endoscopic Evaluation of Swallowing in 2,820 Examinations
复制标题
DOI：
10.1159/000446985
复制
发表时间：
2016-01-01
影响因子：
1
通讯作者：
Fattori, Bruno
中科院分区：
文献类型：
--
作者：
Nacci, Andrea;Matteucci, Jacopo;Fattori, Bruno
目的：回顾性分析2820例内镜下吞咽检查（FEES）并发症及不良事件的发生率。患者和方法：受试者包括比萨大学医院因吞咽困难症状由其他医生转诊的住院和门诊患者。在接受检测的患者中，最常被诊断为神经系统疾病（48.3%）。获得了所有受试者的知情同意。结果：本研究副作用轻微（不适，偶有呛呕吐），并发症少[前鼻出血3例（0.1%），后鼻出血1例（0.04%），血管迷走神经性晕厥3例（0.1%），喉痉挛2例（0.07%）]。这些病例喉痉挛发生在肌萎缩性侧索硬化症（ALS）患者中，并在一些困难后自行消退。结论：我们的研究证实了已发表的关于FEES安全性和并发症发生率的数据，但也强调了在神经退行性疾病（如ALS）的神经系统患者中，喉痉挛更有可能作为严重并发症发生。FEES的总体风险是最小的，但建议临床医生在识别不良反应的体征和症状方面接受良好的培训，并准备好在发生不良反应时采取适当的措施。(C) 2016 S. Karger AG，巴塞尔
Objective: To perform a retrospective evaluation of the incidence of complications and adverse events during fiberoptic endoscopic evaluation of swallowing (FEES) in 2,820 examinations. Patients and Methods: Subjects included inand outpatients at Pisa University Hospital referred for FEES by other physicians due to dysphagia symptoms. Neurologic diseases were the most commonly diagnosed conditions in the patients tested (48.3%). Informed consent was obtained from all subjects. Results: Our study showed minor side effects (discomfort, occasional gagging and vomiting) and a few complications [three cases of anterior epistaxis (0.1%), one case of posterior epistaxis (0.04%), three cases of vasovagal syncope (0.1%) and two cases of laryngospasm (0.07%)]. These cases of laryngospasm occurred in patients with amyotrophic lateral sclerosis (ALS) and spontaneously resolved after some difficulty. Conclusions: Our study confirms the published data regarding the safety of FEES and the incidence of complications with this procedure, but also highlights that in neurologic patients with neurodegenerative diseases such as ALS, laryngospasm is more likely to occur as a severe complication. The overall risk of FEES is minimal, but it is recommended that clinicians be well trained in recognising the signs and symptoms of adverse reactions and be ready to take appropriate action if these occur. (C) 2016 S. Karger AG, Basel